Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.

Nicholas C TurnerRebecca A DentJoyce O'ShaughnessySung-Bae KimSteven J IsakoffCarlos BarriosShigehira SajiIgor BondarenkoZbigniew NoweckiQinshu LianSarah-Jayne ReillyHeather HintonMatthew J WongchenkoBruno KovicAruna ManiMafalda Oliveira

Published in: Breast cancer research and treatment (2021)

Adding ipatasertib to paclitaxel did not improve efficacy in PIK3CA/AKT1/PTEN-altered HR+ HER2-negative aBC. The ipatasertib-paclitaxel safety profile was consistent with each agent's known adverse effects. Trial registration NCT03337724.

Keyphrases

cell proliferation
phase iii
signaling pathway
pi k akt
phase ii
open label
clinical trial
double blind
chemotherapy induced
study protocol
randomized controlled trial